Overview
Investment Type
Venture Capital
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 13, 2013 | New non-invasive test for prostate cancer may identify severity of tumor also | Exosome Diagnostics, Inc. has recently conducted a multi-center clinical study program for EXO106, the first in vitro urinary exosome-derived RNA diagnostic for prostate cancer. Current diagnostic procedures for prostate cancer involve a pr... |
| Dec 12, 2012 | Cerapedics Completes $19M Series C Financing | Cerapedics, Inc., a Westminster, Colorado-based medical device company, has completed a $19m Series C financing. The round was led by new investors MedImmune Ventures and CVF LLC, an affiliate of Henry Crown and Company, with participation ... |
| Apr 8, 2009 | Aerovance inhales $38M for asthma drugs | Aerovance, developer of asthma medications, just brought in $38 million in a post-recapitalized third round of funding to push its lead drug candidate through a second phase of clinical trials. The company has already received $20 million, ... |
| Nov 3, 2008 | Optiscan adds $5M tranche for glucose monitor | Optiscan Biomedical, developer of a less-invasive human glucose monitor for hospitals, received an additional $5 million in a second round of funding that now totals $53 million. The boost came from Wexford Capital, reports VentureWire. The... |
| Jun 5, 2007 | Ultrasound clot-buster Ekos raises $10M in debt | Ekos, a Bothell, Wash., maker of ultrasound-enhanced drug-delivery systems, raised $10 million in debt capital from Hercules Technology Growth Capital. The financing will support the sales and marketing of drug-delivery catheters that featu... |
| New non-invasive test for prostate cancer may identify severity of tumor also | Exosome Diagnostic, Inc., has developed a revolutionary non-invasive approach to molecular diagnostic testing that is gaining popularity, especially in the field of prostate cancer detection and prognosis. The company, based in New York, wa... |
Reviews 0
FAQ about NGN Capital
What has the press written about NGN Capital?
Parsers VC has collected 7 articles mentioning NGN Capital, among them “New non-invasive test for prostate cancer may identify severity of tumor also” (Aug 13, 2013) and “Cerapedics Completes $19M Series C Financing” (Dec 12, 2012).
Is NGN Capital still active?
Yes, NGN Capital is active; its latest activity on Parsers VC dates from Nov 27, 2013.